Pharsight

Drugs that contain Propofol

1. Diprivan patents expiration

DIPRIVAN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8476010 FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Dec, 2024

(5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5908869 FRESENIUS KABI USA Propofol compositions containing edetate
Mar, 2015

(9 years ago)

US5714520 FRESENIUS KABI USA Propofol compostion containing edetate
Mar, 2015

(9 years ago)

US5731355 FRESENIUS KABI USA Pharmaceutical compositions of propofol and edetate
Mar, 2015

(9 years ago)

US5731356 FRESENIUS KABI USA Pharmaceutical compositions of propofol and edetate
Mar, 2015

(9 years ago)

US5908869

(Pediatric)

FRESENIUS KABI USA Propofol compositions containing edetate
Sep, 2015

(8 years ago)

US5731355

(Pediatric)

FRESENIUS KABI USA Pharmaceutical compositions of propofol and edetate
Sep, 2015

(8 years ago)

US5714520

(Pediatric)

FRESENIUS KABI USA Propofol compostion containing edetate
Sep, 2015

(8 years ago)

US5731356

(Pediatric)

FRESENIUS KABI USA Pharmaceutical compositions of propofol and edetate
Sep, 2015

(8 years ago)

US8476010

(Pediatric)

FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Jun, 2025

(11 months from now)

Market Authorisation Date: 02 October, 1989

Treatment: Method of improving the time for administration or the time between changes of giving sets for the drug product; Method of producing anesthesia; Method for limiting the potential for microbial growth ...

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DIPRIVAN before it's drug patent expiration?
More Information on Dosage

DIPRIVAN family patents

Family Patents